statistiche ricercatore

Continente	#
NA - Nord America	549
AS - Asia	325
EU - Europa	252
SA - Sud America	32
AF - Africa	20
Continente sconosciuto - Info sul continente non disponibili	18
OC - Oceania	3
Totale	1.199

Nazione	#
US - Stati Uniti d'America	518
CN - Cina	158
IE - Irlanda	77
SG - Singapore	69
RU - Federazione Russa	37
VN - Vietnam	37
HK - Hong Kong	33
IT - Italia	32
BR - Brasile	22
DE - Germania	21
FI - Finlandia	20
FR - Francia	18
CA - Canada	13
GB - Regno Unito	11
EG - Egitto	7
IN - India	7
MX - Messico	7
ZA - Sudafrica	6
ES - Italia	4
JP - Giappone	4
SE - Svezia	4
TR - Turchia	4
TT - Trinidad e Tobago	4
BE - Belgio	3
CL - Cile	3
IS - Islanda	3
NL - Olanda	3
UA - Ucraina	3
AR - Argentina	2
AT - Austria	2
BD - Bangladesh	2
CO - Colombia	2
HN - Honduras	2
HU - Ungheria	2
ID - Indonesia	2
IQ - Iraq	2
KR - Corea	2
NO - Norvegia	2
NZ - Nuova Zelanda	2
PL - Polonia	2
SV - El Salvador	2
AL - Albania	1
AU - Australia	1
BA - Bosnia-Erzegovina	1
BO - Bolivia	1
CW - ???statistics.table.value.countryCode.CW???	1
DK - Danimarca	1
DZ - Algeria	1
EC - Ecuador	1
ET - Etiopia	1
GR - Grecia	1
GT - Guatemala	1
IR - Iran	1
KE - Kenya	1
KW - Kuwait	1
KZ - Kazakistan	1
LT - Lituania	1
LV - Lettonia	1
MA - Marocco	1
MY - Malesia	1
NG - Nigeria	1
NI - Nicaragua	1
PK - Pakistan	1
PR - Porto Rico	1
RO - Romania	1
SK - Slovacchia (Repubblica Slovacca)	1
TN - Tunisia	1
VE - Venezuela	1
ZW - Zimbabwe	1
Totale	1.182

Nome	#
Methodological and practical issues in TMDD modeling with application to oncology	169
Evaluation of software tools for Bayesian estimation on population models:an update based on current software versions	142
Methods and tools for multiscale modelling in Systems Pharmacology: a review	139
Evaluation of software tools for Bayesian estimation on population models with count and continuous data	128
MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues	124
Current mathematical models for cancer drug discovery	114
Mathematical modeling of efficacy and safety for anticancer drugs clinical development	103
Assessing drug effect from distributional data: A population approach with application to Duchenne Muscular Dystrophy treatment	102
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial	95
Pharmacokinetic Models for Drug and Metabolites Including First Pass Effects: A Priori and A Posteriori Identifiability Analysis	83
Totale	1.199

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	40	0	0	0	0	0	1	0	2	0	1	9	27
2022/2023	170	20	20	5	10	13	9	0	5	82	2	4	0
2023/2024	72	14	10	0	2	2	10	8	15	2	2	4	3
2024/2025	178	7	13	4	2	7	10	3	15	53	5	19	40
2025/2026	453	44	36	23	36	72	20	75	17	38	48	19	25
2026/2027	114	5	23	24	36	26	0	0	0	0	0	0	0
Totale													1.199